指南与共识MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓增生异常综合征异基因造血干细胞移植中的胚系易感特征:基于调查的研究与欧洲血液与骨髓移植学会慢性恶性肿瘤工作组立场声明

Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
指南 / 共识 · Lancet Haematol · 2023-10-25

该立场声明基于欧洲血液与骨髓移植学会(EBMT)网络的电子调查,汇总了欧洲各中心在骨髓增生异常综合征(MDS)异基因造血干细胞移植中胚系易感特征的检测与临床决策现状,并由多学科专家组讨论形成针对供者选择、预处理方案、移植物抗宿主病预防及遗传咨询等环节的协调建议。

要点

  • 全外显子或全基因组测序揭示大量易感髓系肿瘤的胚系变异,对MDS移植的供者选择、预处理和遗传咨询有重要影响。
  • 目前尚无国际指南统一MDS移植中胚系易感特征的管理方法,检测应用因中心经验、国家、医疗体系和法规而异。
  • 专家组基于EBMT调查结果形成本立场声明,提出针对此类临床情况的协调建议。

核心结论

  • 专家组基于EBMT调查结果,针对MDS异基因造血干细胞移植中胚系易感特征的临床管理提出协调建议,涵盖供者选择、预处理方案、移植物抗宿主病预防及亲属遗传咨询。

研究设计与样本

  • 本研究为基于调查的研究与立场声明,由EBMT慢性恶性肿瘤工作组组织,向有MDS移植经验的EBMT中心发放电子调查以了解欧洲现状。
  • 由血液科医生、移植医生、儿科医生、护士及分子生物学与体质遗传学专家组成的国际专家组通过多次线上会议讨论调查结果并制定建议。

主要发现

  • 全外显子或全基因组测序的应用揭示了大量易感髓系疾病(尤其是骨髓增生异常肿瘤)的胚系变异。
  • MDS患者携带此类变异对造血干细胞移植有重要临床影响,涉及供者选择、预处理方案、移植物抗宿主病预防及亲属遗传咨询。
  • 目前尚无国际指南统一此类临床情况的管理方法,胚系检测的应用及其如何指导临床决策因个体临床实践的专业经验以及不同国家、医疗体系和法规而异。

关键数值与推荐

  • 原文未报告具体的推荐条款、推荐等级或关键数值。

临床怎么用

  • 原文未据此给出具体的临床推荐;专家组形成的协调建议见立场声明全文。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent application of whole exome or whole genome sequencing unveiled a plethora of germline variants predisposing to myeloid disorders, particularly myelodysplastic neoplasms. The presence of such variants in patients with myelodysplastic syndromes has important clinical repercussions for haematopoietic stem-cell transplantation, from donor selection and conditioning regimen to graft-versus-host disease prophylaxis and genetic counselling for relatives. No international guidelines exist to harmonise management approaches to this particular clinical scenario. Moreover, the application of germline testing, and how this informs clinical decisions, differs according to the expertise of individual clinical practices and according to different countries, health-care systems, and legislations. Leveraging the global span of the European Society for Blood and Marrow Transplantation (EBMT) network, we took a snapshot of the current European situation on these matters by disseminating an electronic survey to EBMT centres experienced in myelodysplastic syndromes transplantation. An international group of haematologists, transplantation physicians, paediatricians, nurses, and experts in molecular biology and constitutional genetics with experience in myelodysplastic syndromes contributed to this Position Paper. The panel met during multiple online meetings to discuss the results of the EBMT survey and to establish suggested harmonised guidelines for such clinical situations, which are presented here.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Gurnari C, Robin M, Godley LA, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023. PMID: 37898151. doi:10.1016/S2352-3026(23)00265-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。